Cardiovascular & Metabolic Disease

whitePaper | November 24, 2022

The life sciences industry has been exploring ways to accelerate the study start up process for well over a decade. The industry has long understood the value behind faster clinical trials: the sooner clinical trial results can be delivered to agencies

whitePaper | March 17, 2021

To achieve personalization in healthcare for the masses, overcoming specific challenges are needed in order to build a system where all children born today can have access to the best healthcare available.Mass Personalization for Medical Device Therapy tells us on how to Go from Successfully Treating One Patient to One Million

whitePaper | December 21, 2021

This paper suggests that a more simplified approach to modernizing healthcare security operations is warranted. It suggests that a renewed focus on foundational enhancements presents a more rational path to maturity. The "blocking and tackling" sports analogy comes to mind, as only teams that effectively execute at this level can successfully move to the next.

whitePaper | February 15, 2022

Every provider wants to innovate to drive transformation that helps reduce variability, improve efficiency, and support optimal patient care. The question is, how disruptive, in a positive sense, is your innovation? Most innovations in provider organizations are, in truth, iterative tweaks. While tweaks are the cornerstone of continuous improvement lifecycles, iteration isn’t the kind of transformation needed in healthcare. Real innovation creates a disruptive solution that fundamentally changes how people and processes work together, for the better.

whitePaper | July 5, 2022

This whitepaper on atopic dermatitis patient recruitment explores the challenges faced by sponsors, CROs and study sites in enrolling sufficient numbers of patients for their clinical trials.

whitePaper | September 28, 2022

Specialty drugs span a wide range of disease states, from the more prevalent, yet complex, such as multiple sclerosis, to rare and orphan diseases, such as hereditary angioedema (HAE).